Skip to content

Clinical and molecular prognostic factors in newly diagnosed pediatric T-cell lymphoblastic lymphoma: a prospective, multicenter, single-arm phase 2 clinical trial

Jul 2026 · World Journal of Pediatrics · Vol 22, pp. 741 - 754 · 0 citations · 30 references
Medicine

TL;DR

Adjusting the risk stratification based on treatment response significantly improved the overall prognosis of T-LBL, and molecular genetic risk factors might contribute to further risk stratification and provide potential therapeutic targets.

View source

Similar papers

Open access Aug 2026

Clinical Outcome and Prognostic Factors in Childhood Acute Lymphoblastic Leukemia—A Retrospective Cohort Study of Patients from Southern Mexico

Survival outcomes in this cohort are markedly lower than in high-income countries, and improving survival requires complementing biological risk stratification with targeted strategies to overcome socioeconomic barriers and prevent treatment non-adherence.

Francisca Morales-Vital, Diego Moreno-Loaeza, V. M. Alvarado-Castro et al. · 0 citations
Open access Sep 2026

Clinical characteristics, prognosis, and achievement of transplant in adolescents and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in Argentina

Introduction Data on clinical outcomes and allogeneic stem cell transplantation for Latin American Philadelphia chromosome-negative acute lymphoblastic leukemia patients are limited. This study aimed to characterize this population and identify factors influencing overall survival among adolescents and adults with this...

M. M. Clavijo, J. Ruiz, Luciana Ferrari et al. · 0 citations
Oct 2026

Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

BACKGROUND TP53 mutations confer poor prognosis and heterogeneous clinical features in myeloid neoplasms, but distinguishing factors between AML and MDS and independent prognostic markers within this high-risk group remain unclear. METHODS This retrospective study evaluated 45 adult patients with TP53-mutated acute m...

Xiao-Qin Xin, Yan-Hong Li, Xiao-Yu Li · 0 citations
Open access 2026

Prognostic Factors in Advanced Bladder Cancer: A Real-World Retrospective Analysis

Introduction: Metastatic bladder cancer (mBC) is associated with poor outcomes. Despite advances in immunotherapy and targeted agents, platinum-based chemotherapy remains a cornerstone of treatment in real-world practice. We aimed to identify pragmatic and readily available prognostic factors for risk stratification in...

Zeynep Alaca Topçu, M. Ozturk, M. Yıldırım et al. · 0 citations
Open access Sep 2026

Tumor regression grades in locally advanced gastroesophageal adenocarcinoma: associations with survival, pathological risk factors, and molecular biomarkers in a 19-year real-world cohort

Background Tumor regression grade (TRG) after neoadjuvant therapy has been proposed as a prognostic marker in resectable gastroesophageal adenocarcinoma, yet its independent value beyond pathological staging remains uncertain. Materials and methods This retrospective single-center study included 692 patients with local...

H. Puhr, B. Mozayani, M. Korpan et al. · 0 citations
Open access Sep 2026

Composite clinical scores in real-world extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy.

BACKGROUND Composite scores such as Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), EPSILoN, Pan Immune-Inflammation Value (PIV) and Systemic Immune-Inflammation Index (SII) have shown prognostic value in solid tumors, but evidence in extensive-stage small-cell lung cancer (ES-SCLC) are l...

Teresa Beninato, Giulia Stasi, G. Montelatici et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.